1-7 of 7
Jennifer Sun
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

3D Tissue-Engineered Bone Marrow Culture Predicts Patient Response to Drugs in Multiple Myeloma

Kinan Alhallak, Amanda Jeske, Pilar De La Puente, Jennifer Sun, Mark A. Fiala, Feda Azab, Barbara Muz, Ilyas Sahin, Ravi Vij, John F. DiPersio, Abdel Kareem Azab
Journal: Blood
Blood (2021) 138 (Supplement 1): 2690.
https://doi.org/10.1182/blood-2021-153832
Published: 2021
Journal Articles

Inhibition of HIF-1a By PX-478 Normalizes Blood Vessels, Improves Drug Delivery and Suppresses Progression and Dissemination in Multiple Myeloma

Barbara Muz, PhDMSc, Katherine Wasden, Kinan Alhallak, BSc, Amanda Jeske, BS, Feda Azab, Jennifer Sun, BSc, Justin King, BS, Daniel R. Kohnen, MBA, Ravi Vij, MBBS, Abdel Kareem Azab, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 3.
https://doi.org/10.1182/blood-2020-142154
Published: 2020
Journal Articles

ZUMA-11: A Phase 1/2 Multicenter Study of Axicabtagene Ciloleucel (Axi-Cel) + Utomilumab Patients with Refractory Large B Cell Lymphoma

Ran Reshef, MDMSc, David B. Miklos, MD PhD, John M. Timmerman, MD, Caron A. Jacobson, MD MMSc, Nabila N. Bennani, MD, John M. Rossi, MS, Marika Sherman, MS, Lianqing Zheng, PhD, Jennifer Sun, MS, Gabrielle Palluconi, BS, Jenny J. Kim, MD MS, Michael D. Jain, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4084.
https://doi.org/10.1182/blood-2019-123772
Published: 2019
Journal Articles

A Phase 2, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Axicabtagene Ciloleucel in Combination with Either Rituximab or Lenalidomide in Patients with Refractory Large B-Cell Lymphoma (ZUMA-14)

Sattva S Neelapu, MD, Mohamed A Kharfan-Dabaja, MDMBA, Olalekan O. Oluwole, MBBS, MPH, Patel Krish, MD, Ran Reshef, MDMSc, Peter A. Riedell, MD, Parveen Shiraz, MD, Patrick J. Stiff, MD, Jose Villasboas, MD, Lovely Goyal, PhD, Jun Kawashima, Francesca Milletti, PhD, Edward Oliva, Jennifer Sun, MS, Javier Munoz, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4093.
https://doi.org/10.1182/blood-2019-126369
Published: 2019
Journal Articles

Overcoming Drug Resistance in Myeloma By Synchronized Delivery of Therapeutic and Bone Marrow Disrupting Agents By Nanoparticles Targeting Tumor-Associated Endothelium

Cinzia Federico, PhD, Barbara Muz, PhDMSc, Jennifer Sun, BSc, Kinan Alhallak, BSc, Justin King, Daniel R. Kohnen, MBA, Mark A. Fiala, BS, Aldo M. Roccaro, MDPhD, Ravi Vij, MBBS, Abdel Kareem Azab, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1931.
https://doi.org/10.1182/blood-2018-99-118251
Published: 2018
Journal Articles

End of Phase 1 Results from Zuma-6: Axicabtagene Ciloleucel (Axi-Cel) in Combination with Atezolizumab for the Treatment of Patients with Refractory Diffuse Large B Cell Lymphoma

Caron A. Jacobson, MD MMSc, Frederick L. Locke, MD, David B. Miklos, MD PhD, Alex F. Herrera, MD, Jason R. Westin, MD, Jennifer Lee, John M. Rossi, MS, Lianqing Zheng, PhD, Mauro P. Avanzi, MD, Zachary J. Roberts, MD, PhD, Jennifer Sun, MS
Journal: Blood
Blood (2018) 132 (Supplement 1): 4192.
https://doi.org/10.1182/blood-2018-99-111523
Published: 2018
Journal Articles

Silent Cerebral Infarctions in Children and Adolescents with Hemoglobin SC Disease

Jennifer Sun, MPH, Monica L. Hulbert, MD
Journal: Blood
Blood (2012) 120 (21): 1011.
https://doi.org/10.1182/blood.V120.21.1011.1011
Published: 2012